TrialJNCI cancer spectrum2025

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial.

Hanna Bandos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.